Lataa...
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
AIMS: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal events. Recent trials of novel treatments have been negative, possibly because of variability in response to treatment of the target risk factor. Atrasentan is a selective endothelin A receptor antagonist tha...
Tallennettuna:
| Julkaisussa: | Diabetes Obes Metab |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Blackwell Publishing Ltd
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5969254/ https://ncbi.nlm.nih.gov/pubmed/29405626 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13245 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|